Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedOct 24, 2025
DataAggregated Company Financials
Companies297
  • 7D0.8%
  • 3M4.5%
  • 1Y-4.0%
  • YTD5.8%

Last week, the Pharma industry hasn't moved much but Merck is up 3.9% in that time. As for the longer term, the industry has declined 4.0% in the last year. Earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 24 Oct 2025US$1.9tUS$389.2bUS$63.5b18.4x29.6x4.8x
Sun, 21 Sep 2025US$1.8tUS$387.9bUS$60.9b18.4x29x4.6x
Tue, 19 Aug 2025US$1.7tUS$387.8bUS$60.9b19.1x28.6x4.5x
Thu, 17 Jul 2025US$1.7tUS$382.7bUS$61.3b17.9x28.2x4.5x
Sat, 14 Jun 2025US$1.8tUS$382.7bUS$61.2b17.8x29.1x4.7x
Mon, 12 May 2025US$1.7tUS$382.6bUS$61.1b17x27.1x4.3x
Wed, 09 Apr 2025US$1.6tUS$379.9bUS$40.6b15.1x40.5x4.3x
Fri, 07 Mar 2025US$2.0tUS$381.1bUS$39.3b16.3x50x5.2x
Sun, 02 Feb 2025US$1.9tUS$370.4bUS$29.8b18.4x62x5x
Tue, 31 Dec 2024US$1.8tUS$369.3bUS$31.3b16.4x57.7x4.9x
Thu, 28 Nov 2024US$1.9tUS$373.8bUS$30.6b19.8x60.6x5x
Sat, 26 Oct 2024US$2.0tUS$365.3bUS$23.7b17.9x83.8x5.4x
Mon, 23 Sep 2024US$2.0tUS$364.2bUS$25.3b18.9x80.4x5.6x
Wed, 21 Aug 2024US$2.0tUS$362.1bUS$21.8b17.8x92.1x5.5x
Fri, 19 Jul 2024US$2.0tUS$356.5bUS$13.1b16x153.1x5.6x
Sun, 16 Jun 2024US$1.9tUS$358.3bUS$14.1b15.3x137.4x5.4x
Tue, 14 May 2024US$1.9tUS$358.2bUS$13.8b18x134.6x5.2x
Thu, 11 Apr 2024US$1.8tUS$355.1bUS$23.9b23.4x77.3x5.2x
Sat, 09 Mar 2024US$1.9tUS$357.3bUS$20.0b21.9x94x5.3x
Mon, 05 Feb 2024US$1.8tUS$353.1bUS$22.0b31.7x81.4x5.1x
Wed, 03 Jan 2024US$1.7tUS$375.2bUS$33.8b27.4x51x4.6x
Fri, 01 Dec 2023US$1.6tUS$375.1bUS$33.9b26.6x48.2x4.4x
Sun, 29 Oct 2023US$1.6tUS$383.5bUS$46.6b14.2x34.1x4.1x
Tue, 26 Sep 2023US$1.7tUS$381.8bUS$43.9b19.9x38.3x4.4x
Thu, 24 Aug 2023US$1.8tUS$381.6bUS$44.1b19x40.2x4.6x
Sat, 22 Jul 2023US$1.7tUS$394.3bUS$60.5b18.6x28.7x4.4x
Mon, 19 Jun 2023US$1.7tUS$392.8bUS$60.1b19x29x4.4x
Wed, 17 May 2023US$1.7tUS$393.1bUS$60.4b19.3x28.5x4.4x
Fri, 14 Apr 2023US$1.7tUS$401.3bUS$68.5b17.7x24.5x4.2x
Sun, 12 Mar 2023US$1.5tUS$401.1bUS$69.6b17.4x21.9x3.8x
Tue, 07 Feb 2023US$1.7tUS$402.0bUS$69.9b18.2x23.7x4.1x
Thu, 05 Jan 2023US$1.8tUS$403.7bUS$70.7b17.1x24.8x4.3x
Sat, 03 Dec 2022US$1.8tUS$403.7bUS$70.7b17.2x25.3x4.4x
Mon, 31 Oct 2022US$1.7tUS$404.8bUS$70.8b16.1x24.1x4.2x
Price to Earnings Ratio

24.1x


Total Market Cap: US$1.7tTotal Earnings: US$70.8bTotal Revenue: US$404.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.6x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 29.6x which is lower than its 3-year average PE of 52.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 3.6% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.29%
Healthcare2.04%
Pharma0.81%
Pharma0.81%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$825.452.8%
+US$20.3b		-7.5%PE53.7x
MRK MerckUS$87.493.2%
+US$6.7b		-15.9%PE13.3x
PFE PfizerUS$24.761.0%
+US$1.4b		-13.0%PE13.1x
ZTS ZoetisUS$146.191.5%
+US$944.0m		-18.8%PE24.8x
NUVB Nuvation BioUS$4.8542.2%
+US$492.9m		119.5%PS115.6x

Latest News

LLY
US$825.45
Eli Lilly
7D
2.8%
1Y
-7.5%
JNJ
US$190.40
Johnson & Johnson
7D
-1.5%
1Y
18.3%
MRK
US$87.49
Merck
7D
3.2%
1Y
-15.9%
TEVA
US$18.95
Teva Pharmaceutical Industries
7D
-1.9%
1Y
5.9%

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries

Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.
AVDL
US$18.56
Avadel Pharmaceuticals
7D
23.7%
1Y
42.8%

Analysts Adjust Avadel Pharmaceuticals Price Target Amid Acquisition and Ongoing Market Developments

Analysts have lowered their price target for Avadel Pharmaceuticals to $20 from previous higher levels. They cite the pending acquisition by Alkermes at $18.50 per share, plus a potential $1.50 contingent cash right, as the primary driver behind the adjustment.
ELAN
US$22.05
Elanco Animal Health
7D
2.9%
1Y
77.7%
NUVB
US$4.85
Nuvation Bio
7D
42.2%
1Y
119.5%
CORT
US$72.42
Corcept Therapeutics
7D
-8.0%
1Y
53.2%
PFE
US$24.76
Pfizer
7D
1.0%
1Y
-13.0%
TARS
US$66.07
Tarsus Pharmaceuticals
7D
-9.4%
1Y
67.6%

Market Participants Recognise Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Revenues Pushing Shares 41% Higher

Oct 18
Market Participants Recognise Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Revenues Pushing Shares 41% Higher
ZTS
US$146.19
Zoetis
7D
1.5%
1Y
-18.8%

Companion Animal And Livestock Demand Will Unlock Future Opportunities

Analysts have slightly lowered their price target for Zoetis from $189.22 to $188.83, citing modest revisions to revenue growth estimates. They also noted a marginal increase in expected profit margins.
BMY
US$43.83
Bristol-Myers Squibb
7D
0.5%
1Y
-15.6%
OCUL
US$11.44
Ocular Therapeutix
7D
-6.2%
1Y
5.1%

Future Drug Approvals Will Expand Retinal Disease Treatments

Ocular Therapeutix saw its analyst price target increase significantly from $20 to $29, as analysts cite newly available de-risked data in Nonproliferative Diabetic Retinopathy and upcoming pivotal readouts in wet AMD as key drivers of enhanced valuation. Analyst Commentary Following the recent price target revision, analysts have weighed in with both optimistic and cautious perspectives regarding Ocular Therapeutix's outlook.
OMER
US$7.65
Omeros
7D
-22.2%
1Y
80.4%
LENZ
US$31.96
LENZ Therapeutics
7D
-16.5%
1Y
18.3%
RGC
US$15.90
Regencell Bioscience Holdings
7D
-8.7%
1Y
12,893.6%